Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2012 - 2026)

Catalyst Pharmaceuticals (CPRX) has 11 years of Long-Term Deferred Tax data on file, last reported at $55.1 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 14.29% year-over-year to $55.1 million; the trailing twelve-month figure through Mar 2026 stood at $55.1 million (up 14.29% YoY), and the FY2025 full-year result was $52.8 million, up 14.76% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $55.1 million, up from $52.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $55.1 million in Q1 2026 and bottomed at $18.7 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $38.3 million (2024), against an average of $36.9 million.
• The widest annual swing landed in 2022, when Long-Term Deferred Tax slumped 30.33%; it then jumped 95.05% in 2023.
• A 5-year view of Long-Term Deferred Tax shows it stood at $18.7 million in 2022, then surged by 95.05% to $36.5 million in 2023, then advanced by 25.83% to $46.0 million in 2024, then climbed by 14.76% to $52.8 million in 2025, then gained by 4.44% to $55.1 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $55.1 million (Q1 2026), $52.8 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.

Peer Comparison